Mechanism
GLP-3 and retatrutide
GLP-3 is a shorthand people use in search and some listings for retatrutide's triple-action profile. The formal description is not "a GLP-3 drug"; Lilly describes retatrutide as a triple hormone receptor agonist that activates GIP, GLP-1, and glucagon receptors.
Key takeaways
- GLP-3 retatrutide searches usually refer to triple receptor activity.
- The three receptor targets are GIP, GLP-1, and glucagon.
- Clinical-trial interest does not mean retatrutide is approved or publicly available.
- Supplier terms such as GLP-3RT should be treated as listing language, not official drug status.
What does GLP-3 mean?
In retatrutide search behavior, GLP-3 is best understood as an informal label for a triple-receptor concept. It is used because retatrutide is being studied for effects at three hormone receptor pathways rather than one.
The more precise wording is triple hormone receptor agonist. Lilly names the receptor targets as glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon.
Why this matters for searchers
Informal shorthand can blur the line between scientific mechanism and commercial claim. If a public page says GLP-3, GLP-3 retatrutide, or GLP-3RT, the next question is not whether the phrase sounds advanced. The next question is whether the page is official, whether it is a clinical-trial record, and whether it makes public-use claims that need verification.
What retatrutide does in trials
A phase 2 obesity trial published in the New England Journal of Medicine reported substantial body-weight reductions over 48 weeks and also evaluated safety. Lilly is studying retatrutide further in Phase 3 clinical trials. This site does not translate trial results into treatment recommendations.